Liver Cancer Registry Platform

Launched by IOMEDICO AG · Aug 10, 2020

Keywords

ClinConnect Summary

The Liver Cancer Registry Platform is a clinical trial aimed at better understanding two types of liver cancer: Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CCC). This study will gather information about patients’ cancer characteristics, treatments, and how the disease affects their lives over time. It will also create a biobank, which is a collection of biological samples that can be used for future research. The goal is to improve care for patients with these conditions by collecting uniform data from multiple medical centers across Germany.

To participate, individuals must be at least 18 years old and have a confirmed diagnosis of either HCC or CCC at any stage of the disease. Participation involves signing a consent form and may include reporting on how the treatment affects their quality of life. Patients receiving only supportive care, with no active treatment like surgery or chemotherapy, are not eligible for this study. Those who join can expect to contribute valuable information that may help improve treatments and outcomes for future patients with liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/metastatic stage
• • Age ≥ 18 years
• * Signed and dated informed consent (IC):
• • For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment
• • For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment
• Exclusion criteria:
• • Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)